世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

医薬品ドラッグデリバリー市場：投与経路別（経口、注射器、インプラント、シロップ、ゲル、肺、溶液、錠剤、シリンジ）、用途別（がん、糖尿病）、使用施設別（病院）、COVID-19インパクト - 2026年までの世界予測


Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals), COVID-19 Impact - Global Forecast to 2026

世界のドラッグデリバリー市場は、2021年の1兆6,569億米ドルから、2026年には2兆2,065億米ドルに達すると予測され、予測期間中のCAGRは5.9%となります。薬物送達市場の成長は、慢性疾患の有病率の上昇、生物製剤... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2021年11月17日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		556 690 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界のドラッグデリバリー市場は、2021年の1兆6,569億米ドルから、2026年には2兆2,065億米ドルに達すると予測され、予測期間中のCAGRは5.9%となります。薬物送達市場の成長は、慢性疾患の有病率の上昇、生物製剤市場の拡大、研究開発投資の増加、技術の進歩と新製品の発売などの要因に大きく起因しています。
一方で、針刺し事故のリスクや価格圧力の高まりが、今後数年間の市場成長をある程度制限すると予想されます。

予測期間中に最も高いCAGRで成長すると予想されるのは、局所ドラッグデリバリー分野です。
医薬品ドラッグデリバリー市場は、投与経路に基づいて、経口、肺、注射、眼、鼻、外用、移植、経粘膜ドラッグデリバリーに分けられます。医薬品ドラッグデリバリー市場では、外用薬セグメントが最も高いCAGRを示しています。これは、利便性と使いやすさ、投与のしやすさ、痛みのない非侵襲的な投与、患者のコンプライアンスの向上などが要因と考えられます。
医薬品ドラッグデリバリー市場では、感染症分野が最大のシェアを占めると予想されています
医薬ドラッグデリバリー市場は、アプリケーションに基づいて、がん、感染症、循環器系疾患、糖尿病、呼吸器系疾患、中枢神経系疾患、自己免疫疾患、その他のアプリケーションに分類されます。2020年には、感染症分野が医薬ドラッグデリバリー市場で最大のシェアを占めました。これは、世界的に感染症が増加していること、COVID-19パンデミックの影響で新薬の研究開発費が増加していること、FDAによる承認件数が増加していることなどが要因として挙げられます。
アジア太平洋地域は、薬物送達市場を運営するプレイヤーにとって最も高いCAGRを示すと予想される
予測期間中、アジア太平洋地域は、医薬品ドラッグデリバリーの地域市場として最も急速に成長すると予想されています。高齢者人口の急増、慢性疾患の蔓延、医療費の増加、この地域で行われている研究開発活動の増加、薬物送達技術に関する技術提携の増加、有利な償還政策、中国やインドなどのアジア新興国における可処分所得の増加などが、予測期間中にAPAC市場の成長を促進する要因となると考えられます。
主要参加企業の内訳は以下の通りです。
- 企業タイプ別 - Tier 1-35%、Tier 2-45%、Tier 3-20%。
- 企業タイプ別 - 階層1～35%、階層2～45%、階層3～20% ・役職別 - Cレベル-35%、ディレクターレベル-25%、その他-40
- 地域別 - 北米-45%、欧州-30%、アジア-20%、ラテンアメリカ-3%、中東・アフリカ-2

医薬品ドラッグデリバリー市場の主要プレイヤー
この市場の主要プレーヤーは、ジョンソン・エンド・ジョンソン（米国）、ノバルティス・インターナショナルAG（スイス）、F.ホフマン・ラ・ロシュAG（スイス）、ファイザー・インク（米国）、バイエルAG（米国）などです。(米国)、Bayer AG(ドイツ)、Antares Pharma, Inc.(米国）、Becton, Dickinson and Company（米国）、GlaxoSmithKline plc（英国）、3M（米国）、Merck & Co.(米）、Sanofi（仏）、Amgen, Inc.(米)、AbbVie Inc.(米国)、Genmab A/S(デンマーク)、Gilead Sciences, Inc.(米国)、ベーリンガーインゲルハイム(ドイツ)、アストラゼネカplc.(イギリス）、Eli Lilly and Company（アメリカ）、Teva Pharmaceuticals Industries Ltd.(イスラエル）、Bristol-Myers Squibb（米国）、Gerresheimer AG（ドイツ）、Boston Scientific Corporation（米国）、Nimbus Therapeutics（米国）、Kite Pharma（米国）、IDEAYA Biosciences, Inc.(米国)の5社です。
リサーチカバレッジ
当レポートでは、医薬品ドラッグデリバリー市場を分析し、投与経路、用途、使用施設、地域など様々なセグメントに基づいて、同市場の市場規模と今後の成長性を推定することを目的としています。また、市場で入手可能な様々な医薬品ドラッグデリバリーの製品ポートフォリオマトリクスも掲載しています。さらに、この市場における主要企業の競合分析を行い、企業プロフィール、製品・サービス内容、主要な市場戦略などを紹介しています。
本レポートを購入する理由
本レポートは、既存の企業だけでなく、新規参入者や小規模な企業にとっても、市場の動向を把握するのに役立ちます。本レポートを購入した企業は、市場における自社のポジションを強化するために、以下の戦略の1つまたは複数の組み合わせを利用することができます。

本レポートでは、以下の点について分析しています。
- 市場への浸透。世界の医薬品ドラッグデリバリー市場のトッププレーヤーが提供する製品ポートフォリオに関する包括的な情報。本レポートでは、この市場を投与経路、用途、使用施設別に分析しています。
- ソリューションの強化/革新。世界の医薬品ドラッグデリバリー市場における今後の動向と製品の発売に関する詳細な洞察
- 市場開拓。投与経路、アプリケーション、使用施設別の有利な新興市場に関する包括的な情報
- 市場の多様化新製品の強化、成長地域、最近の開発状況、世界の医薬品ドラッグデリバリー市場への投資に関する詳細な情報
- 競合評価世界のドラッグデリバリー市場における主要企業のシェア、成長戦略、製品提供、競合他社とのマッピング、能力などを詳細に評価します。

ページTOPに戻る


目次

1 INTRODUCTION 45
1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION AND SCOPE 45
1.2.1 INCLUSIONS & EXCLUSIONS 45
1.2.2 MARKETS COVERED 46
FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION 46
1.2.3 YEARS CONSIDERED FOR THE STUDY 46
1.3 CURRENCY 47
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 47
1.4 STAKEHOLDERS 47
1.5 SUMMARY OF CHANGES 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH APPROACH 49
FIGURE 2 RESEARCH DESIGN 49
2.1.1 SECONDARY RESEARCH 50
2.1.1.1 Key data from secondary sources 51
2.1.2 PRIMARY RESEARCH 52
FIGURE 3 PRIMARY SOURCES 52
2.1.2.1 Key data from primary sources 53
2.1.2.2 Insights from primary experts 54
2.1.2.3 Breakdown of primaries 54
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND PARTICIPANTS 54
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 55
2.2 MARKET SIZE ESTIMATION 55
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 56
FIGURE 7 PHARMACEUTICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON 56
FIGURE 8 PHARMACEUTICAL SALES APPROACH 57
FIGURE 9 TOP-DOWN APPROACH 57
FIGURE 10 CAGR PROJECTIONS 58
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR 59
2.3 DATA TRIANGULATION APPROACH 61
FIGURE 12 DATA TRIANGULATION METHODOLOGY 61
 
2.4 MARKET SHARE ESTIMATION 62
2.5 ASSUMPTIONS FOR THE STUDY 62
2.6 LIMITATIONS 62
2.6.1 METHODOLOGY-RELATED LIMITATIONS 62
2.7 RISK ASSESSMENT 63
TABLE 2 RISK ASSESSMENT: PHARMACEUTICAL DRUG DELIVERY MARKET 63
3 EXECUTIVE SUMMARY 64
FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD BILLION) 64
FIGURE 14 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION) 65
FIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2021 VS. 2026 (USD BILLION) 66
FIGURE 16 GEOGRAPHIC ANALYSIS: PHARMACEUTICAL DRUG DELIVERY MARKET 67
4 PREMIUM INSIGHTS 69
4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW 69
FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH 69
4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY 70
FIGURE 18 THE HOSPITALS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET IN 2020 70
4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
FIGURE 19 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD 71
4.4 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION (2019-2026) 72
FIGURE 20 NORTH AMERICA TO DOMINATE THE PHARMACEUTICAL DRUG DELIVERY MARKET DURING FORECAST PERIOD 72
4.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS 73
FIGURE 21 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 73
5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
TABLE 3 PHARMACEUTICAL DRUG DELIVERY MARKET: IMPACT ANALYSIS 74
5.2.1 MARKET DRIVERS 75
5.2.1.1 Rising prevalence of chronic diseases 75
5.2.1.2 Growth in the biologics market 76
TABLE 4 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2020) 76
5.2.1.3 Technological advancements and new product launches 77
5.2.1.4 Increasing investments in pharmaceutical R&D 79
FIGURE 22 NUMBER OF PHARMACEUTICAL COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020) 79
FIGURE 23 GLOBAL PHARMA R&D SPENDING (2016–2020) 79
5.2.2 MARKET RESTRAINTS 80
5.2.2.1 Risk of needlestick injuries 80
5.2.3 MARKET OPPORTUNITIES 81
5.2.3.1 Self-administration and home care 81
5.2.3.2 Rising demand for biosimilars and biologics 81
5.2.4 MARKET CHALLENGES 82
5.2.4.1 Pricing pressure 82
5.3 COVID-19 IMPACT ON THE PHARMACEUTICAL DRUG DELIVERY MARKET 82
5.4 INDUSTRY TRENDS 84
5.4.1 INCREASING ADOPTION OF WEARABLE DRUG DELIVERY TECHNOLOGIES 84
5.4.2 ADVANCEMENTS IN TECHNOLOGIES AND DESIGNS 84
5.5 REGULATORY ANALYSIS 85
TABLE 5 REGULATORY SCENARIO BY COUNTRY 85
5.6 PORTER’S FIVE FORCES ANALYSIS 88
TABLE 6 PORTER’S FIVE FORCES ANALYSIS (2020): PHARMACEUTICAL DRUG DELIVERY MARKET 88
5.6.1 THREAT FROM NEW ENTRANTS 88
5.6.2 THREAT FROM SUBSTITUTES 88
5.6.3 BARGAINING POWER OF SUPPLIERS 89
5.6.4 BARGAINING POWER OF BUYERS 89
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 89
5.7 VALUE CHAIN ANALYSIS 90
FIGURE 24 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL DRUG DELIVERY MARKET 90
5.8 ECOSYSTEM MAPPING 91
FIGURE 25 ECOSYSTEM OF THE PHARMACEUTICAL DRUG DELIVERY MARKET 91
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 91
5.10 PATENT ANALYSIS 92
5.10.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 92
FIGURE 26 PATENT PUBLICATION, FILING, AND GRANT TRENDS (JANUARY 2011–OCTOBER 2021) 92
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 92
FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021) 93
FIGURE 28 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021) 94
TABLE 7 SOME PATENTS/ PATENT APPLICATIONS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET, 2020-2021 94
 
6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 96
6.1 INTRODUCTION 97
TABLE 8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 97
6.2 ORAL DRUG DELIVERY 98
TABLE 9 ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 98
TABLE 10 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 99
6.2.1 SOLID ORAL DRUGS 99
TABLE 11 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 100
TABLE 12 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION) 100
6.2.1.1 Tablets 101
6.2.1.1.1 The development of mini-tablets is a key trend in this market segment 101
TABLE 13 TABLETS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 102
6.2.1.2 Capsules 102
6.2.1.2.1 The easy absorption of drugs and decreased irritation in the GI tract drive the use of capsules 102
TABLE 14 CAPSULES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 103
6.2.1.3 Powders 103
6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms 103
TABLE 15 POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 104
6.2.1.4 Pills 105
6.2.1.4.1 The rising incidence of target ailments to propel the growth of the pills market 105
TABLE 16 PILLS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 105
6.2.2 LIQUID ORAL DRUGS 106
TABLE 17 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 106
TABLE 18 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 107
6.2.2.1 Syrups 107
6.2.2.1.1 Syrups can be easily administered to patients with swallowing difficulties 107
TABLE 19 ORAL SYRUPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 108
6.2.2.2 Solutions 108
6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients 108
TABLE 20 ORAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 109
6.2.3 SEMI SOLID ORAL DRUGS 109
TABLE 21 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 110
TABLE 22 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION) 110
6.2.3.1 Gels 111
6.2.3.1.1 Gels are used for controlled drug release 111
TABLE 23 ORAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 111
6.2.3.2 Emulsions 112
6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis 112
TABLE 24 ORAL EMULSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 112
6.2.3.3 Elixirs 113
6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances 113
TABLE 25 ORAL ELIXIRS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 113
6.3 INJECTABLE DRUG DELIVERY 114
TABLE 26 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 115
TABLE 27 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 115
6.3.1 CONVENTIONAL INJECTION DEVICES 116
TABLE 28 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 116
6.3.1.1 By material 117
TABLE 29 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 117
6.3.1.1.1 Glass Syringes 117
6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safest materials to store biological drugs 117
TABLE 30 GLASS SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118
6.3.1.1.2 Plastic Syringes 118
6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts 118
TABLE 31 PLASTIC SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 119
6.3.1.2 By product 119
TABLE 32 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 120
6.3.1.2.1 Fillable syringes 120
6.3.1.2.1.1 Ease of use and the variable dosing formulations of fillable syringes to drive the market growth 120
TABLE 33 FILLABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 121
6.3.1.2.2 Prefilled syringes 121
6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety 121
TABLE 34 PREFILLED SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
6.3.1.3 By usability 123
TABLE 35 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 123
6.3.1.3.1 Reusable syringes 123
6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean 123
TABLE 36 REUSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 124
6.3.1.3.2 Disposable syringes 124
6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience 124
TABLE 37 DISPOSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 125
6.3.2 SELF-INJECTION DEVICES 125
TABLE 38 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 126
TABLE 39 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 127
6.3.2.1 Needle-free injectors 127
6.3.2.1.1 Needle-free injectors enable faster drug delivery and show better reproducibility as compared to invasive drug delivery systems 127
TABLE 40 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 128
6.3.2.2 Autoinjectors 128
6.3.2.2.1 Autoinjectors to provide improved patient satisfaction as compared to manual injections 128
TABLE 41 AUTOINJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 129
6.3.2.3 Pen injectors 129
6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week 129
TABLE 42 COMMERCIALLY AVAILABLE KEY PEN INJECTORS 130
TABLE 43 PEN INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 130
6.3.2.4 Wearable injectors 131
6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth 131
TABLE 44 WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 131
6.3.3 OTHER INJECTOR DEVICES 132
TABLE 45 OTHER INJECTORS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 132
6.4 TOPICAL DRUG DELIVERY 133
TABLE 46 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 133
TABLE 47 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 134
6.4.1 LIQUID FORMULATIONS 134
TABLE 48 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 134
TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 135
6.4.1.1 Solutions 135
6.4.1.1.1 Ease of use and ready availability of the dosage form to support market growth 135
TABLE 50 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 136
 
6.4.1.2 Suspensions 136
6.4.1.2.1 Factors such as the high rate of bioavailability and the controlled onset of action to support the growth of the topical suspensions market 136
TABLE 51 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 137
6.4.2 SEMI SOLID FORMULATIONS 137
TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 138
TABLE 53 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 138
6.4.2.1 Creams 139
6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions 139
TABLE 54 TOPICAL CREAMS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 139
6.4.2.2 Gels 140
6.4.2.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels 140
TABLE 55 TOPICAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 140
6.4.2.3 Ointments 141
6.4.2.3.1 Ointments are widely used in analgesic indications 141
TABLE 56 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 141
6.4.2.4 Pastes 142
6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation 142
TABLE 57 TOPICAL PASTES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 142
6.4.2.5 Lotions 143
6.4.2.5.1 Easy administration of lotions to drive the demand among end users 143
TABLE 58 TOPICAL LOTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 143
6.4.3 SOLID FORMULATIONS 144
TABLE 59 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 144
TABLE 60 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 144
6.4.3.1 Suppositories 145
6.4.3.1.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug 145
TABLE 61 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 145
6.4.3.2 Powders 146
6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight 146
TABLE 62 TOPICAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 146
6.4.4 TRANSDERMAL PRODUCTS 147
TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 147
TABLE 64 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2019–2026 (USD BILLION) 148
6.4.4.1 Transdermal patches 148
6.4.4.1.1 Transdermal patches to prevent the premature metabolization of the drug through the liver 148
TABLE 65 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 149
6.4.4.2 Transdermal gels 150
6.4.4.2.1 Transdermal gels to help in a faster release of drugs on the target site 150
TABLE 66 TRANSDERMAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 150
6.5 OCULAR DRUG DELIVERY 151
TABLE 67 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 151
TABLE 68 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 152
6.5.1 LIQUID FORMULATIONS 152
TABLE 69 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 153
TABLE 70 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 153
6.5.1.1 Eye drops 154
6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth 154
TABLE 71 COMMERCIALLY AVAILABLE EYE DROPS 154
TABLE 72 EYE DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 155
6.5.1.2 Liquid sprays 155
6.5.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops 155
TABLE 73 LIQUID SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 156
6.5.2 SEMI SOLID FORMULATIONS 156
TABLE 74 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 157
TABLE 75 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 157
6.5.2.1 Gels 158
6.5.2.1.1 The high viscosity of drugs, prolonged drug release, and the ease of drug administration are factors contributing to market growth 158
TABLE 76 OCULAR GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 158
6.5.2.2 Eye ointments 159
6.5.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug 159
TABLE 77 EYE OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 160
6.5.3 OCULAR DEVICES 160
TABLE 78 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 161
TABLE 79 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 161
6.5.3.1 Drug-coated contact lenses 162
6.5.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses 162
TABLE 80 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 162
6.5.3.2 Ocular inserts 163
6.5.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye 163
TABLE 81 OCULAR INSERTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 163
6.6 PULMONARY DRUG DELIVERY 164
TABLE 82 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 164
TABLE 83 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 165
6.6.1 METERED-DOSE INHALERS 165
6.6.1.1 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath 165
TABLE 84 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2019–2026 (USD BILLION) 166
6.6.2 DRY POWDER INHALERS 166
6.6.2.1 Dry powder inhaler formulations are chemically more stable than their counterparts 166
TABLE 85 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2019–2026 (USD BILLION) 167
6.6.3 NEBULIZERS 167
TABLE 86 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 168
TABLE 87 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2019–2026 (USD BILLION) 168
6.6.3.1 Jet nebulizers 169
6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market 169
TABLE 88 JET NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 169
6.6.3.2 Ultrasonic nebulizers 170
6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle 170
TABLE 89 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 170
6.6.3.3 Soft mist nebulizers 171
6.6.3.3.1 Soft mist nebulizers are preferred for the treatment of severe COPD 171
TABLE 90 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 171
6.7 NASAL DRUG DELIVERY 172
TABLE 91 NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 172
TABLE 92 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 173
 
6.7.1 NASAL DROPS 173
6.7.1.1 Nasal drops are considered more efficient than nasal sprays 173
TABLE 93 NASAL DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 174
6.7.2 NASAL SPRAYS 174
6.7.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing 174
TABLE 94 NASAL SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 175
6.7.3 NASAL POWDERS 175
6.7.3.1 The absence of preservatives and superior stability of formulations are some of the advantages associated with nasal powders 175
TABLE 95 NASAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 176
6.7.4 NASAL GELS 176
6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients 176
TABLE 96 NASAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 177
6.8 TRANSMUCOSAL DRUG DELIVERY 177
TABLE 97 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 178
TABLE 98 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 179
6.8.1 ORAL FORMULATIONS 179
TABLE 99 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 180
TABLE 100 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 180
6.8.1.1 Buccal drug delivery 181
6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies 181
TABLE 101 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 181
6.8.1.2 Sublingual drug delivery 182
6.8.1.2.1 The rate of drug absorption through the sublingual route is 3–10 times higher than the oral route 182
TABLE 102 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 183
6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES 183
TABLE 103 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 184
TABLE 104 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 184
6.8.2.1 Rectal transmucosal drug delivery 185
6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature 185
TABLE 105 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 185
6.8.2.2 Vaginal transmucosal drug delivery 186
6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration 186
TABLE 106 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 186
6.9 IMPLANTABLE DRUG DELIVERY 187
TABLE 107 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 187
TABLE 108 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 188
6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY 188
6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionizing radiation 188
TABLE 109 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 189
6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY 189
6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants 189
TABLE 110 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 190
7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION 191
7.1 INTRODUCTION 192
7.2 COVID-19 IMPACT, BY APPLICATION 192
TABLE 111 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 193
7.3 INFECTIOUS DISEASES 193
7.3.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH 193
TABLE 112 PHARMACEUTICAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 195
7.4 CANCER 195
7.4.1 CANCER TO FORM A KEY THERAPEUTIC APPLICATION SEGMENT FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 195
FIGURE 29 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020) 196
FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS) 196
TABLE 113 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) 197
TABLE 114 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD BILLION) 198
7.5 CARDIOVASCULAR DISEASES 198
7.5.1 INCREASING PREVALENCE OF CVDS AND INCREASING INNOVATION IN THE PHARMACEUTICAL DRUG DELIVERY SEGMENT TO PROPEL MARKET GROWTH 198
TABLE 115 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 199
TABLE 116 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 200
 
7.6 DIABETES 200
7.6.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 200
FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS) 201
TABLE 117 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD BILLION) 202
7.7 RESPIRATORY DISEASES 202
7.7.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE THE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY 202
TABLE 118 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020) 203
TABLE 119 PHARMACEUTICAL DRUG DELIVERY MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 204
7.8 CENTRAL NERVOUS SYSTEM DISORDERS 204
7.8.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS 204
TABLE 120 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION) 206
7.9 AUTOIMMUNE DISEASES 206
7.9.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD 206
TABLE 121 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 207
7.10 OTHER APPLICATIONS 208
7.10.1 OPHTHALMIC DISORDERS 208
7.10.2 ENDOCRINE DISORDERS 208
TABLE 122 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 209
8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 210
8.1 INTRODUCTION 211
TABLE 123 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 211
8.2 HOSPITALS 212
8.2.1 HOSPITALS DOMINATE THE GLOBAL MARKET WITH THE HIGH VOLUME OF PRESCRIPTIONS FOR INPATIENT AND OUTPATIENT VISITS 212
TABLE 124 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD BILLION) 213
8.3 AMBULATORY SURGERY CENTERS/CLINICS 214
8.3.1 INCREASING PREFERENCE FOR AMBULATORY SURGERY CENTERS TO RESULT IN A SIGNIFICANT RISE IN DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 214
TABLE 125 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD BILLION) 215
 
8.4 HOME CARE SETTINGS 215
8.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 215
TABLE 126 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026 (USD BILLION) 216
8.5 DIAGNOSTIC CENTERS 216
8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH 216
TABLE 127 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2019–2026 (USD BILLION) 217
8.6 OTHER FACILITIES OF USE 217
TABLE 128 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2019–2026 (USD BILLION) 218
9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION 219
9.1 INTRODUCTION 220
FIGURE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2020) 220
TABLE 129 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2019–2026 (USD BILLION) 221
9.2 NORTH AMERICA 221
FIGURE 33 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 223
TABLE 130 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 224
TABLE 131 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 224
TABLE 132 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 225
TABLE 133 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 225
TABLE 134 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 225
TABLE 135 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 226
TABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 226
TABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 226
TABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 227
TABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 227
TABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 227
TABLE 141 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 228
TABLE 142 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 228
TABLE 143 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 228
TABLE 144 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 229
TABLE 145 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 229
TABLE 146 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 229
TABLE 147 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 148 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 149 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 150 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 151 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 152 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 153 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 232
TABLE 154 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 232
TABLE 155 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 232
TABLE 156 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 233
TABLE 157 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 233
TABLE 158 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 234
9.2.1 US 234
9.2.1.1 The US to dominate the North American pharmaceutical drug delivery market 234
TABLE 159 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 235
TABLE 160 US: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 235
TABLE 161 US: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 236
TABLE 162 US: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 236
TABLE 163 US: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 236
TABLE 165 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 237
TABLE 166 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES,
BY MATERIAL, 2019–2026 (USD BILLION) 237
TABLE 167 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 237
TABLE 168 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 238
TABLE 169 US: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 238
TABLE 170 US: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 238
TABLE 171 US: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 239
TABLE 172 US: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 239
TABLE 173 US: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 239
TABLE 174 US: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 240
TABLE 175 US: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 240
TABLE 176 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 240
TABLE 177 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 241
TABLE 178 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 241
TABLE 179 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 241
TABLE 180 US: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 242
TABLE 181 US: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 242
TABLE 182 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 242
TABLE 183 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 184 US: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 185 US: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 186 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 244
TABLE 187 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 244

　

ページTOPに戻る


　

Summary

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period. Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.
On the other hand, the risk of needlestick injuries and the increased pricing pressure is expected to limit the market growth to some extent in the coming years.

The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period
Based on route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery segment accounted for the highest CAGR of the pharmaceutical drug delivery market. This can be attributed to convenience and the ease of use, the ease of dosage, painless and non-invasive administration, and enhanced patient compliance.
The infectious diseases segment is expected to account for the largest share of the pharmaceutical drug delivery market
Based on application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.
Asia Pacific is expected to account for the highest CAGR for players operating in the pharmaceutical drug delivery market
During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market for pharmaceutical drug delivery. The rapid rise in the geriatric population, increased prevalence of chronic diseases, increased healthcare expenditure, increased R&D activities conducted in this region, growth in technological collaborations for pharmaceutical drug delivery technologies, favorable reimbursement policies, and growth in disposable incomes in the emerging Asian economies, such as China and India, are factors that are expected to drive the growth of the APAC market during the forecast period.
Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the Pharmaceutical Drug Delivery Market
Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).
Research Coverage:
The report analyzes the pharmaceutical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as route of administration, application, facility of use, and region. The report also includes a product portfolio matrix of various pharmaceutical drug delivery available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product & service offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global pharmaceutical drug delivery market. The report analyzes this market by route of administration, application, and facility of use
• Solution Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global pharmaceutical drug delivery market
• Market Development: Comprehensive information on the lucrative emerging markets by route of administration, applications, and facility of use
• Market Diversification: Exhaustive information about new product enhancements, growing geographies, recent developments, and investments in the global pharmaceutical drug delivery market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global pharmaceutical drug delivery market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 45
1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION AND SCOPE 45
1.2.1 INCLUSIONS & EXCLUSIONS 45
1.2.2 MARKETS COVERED 46
FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION 46
1.2.3 YEARS CONSIDERED FOR THE STUDY 46
1.3 CURRENCY 47
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 47
1.4 STAKEHOLDERS 47
1.5 SUMMARY OF CHANGES 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH APPROACH 49
FIGURE 2 RESEARCH DESIGN 49
2.1.1 SECONDARY RESEARCH 50
2.1.1.1 Key data from secondary sources 51
2.1.2 PRIMARY RESEARCH 52
FIGURE 3 PRIMARY SOURCES 52
2.1.2.1 Key data from primary sources 53
2.1.2.2 Insights from primary experts 54
2.1.2.3 Breakdown of primaries 54
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND PARTICIPANTS 54
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 55
2.2 MARKET SIZE ESTIMATION 55
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 56
FIGURE 7 PHARMACEUTICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON 56
FIGURE 8 PHARMACEUTICAL SALES APPROACH 57
FIGURE 9 TOP-DOWN APPROACH 57
FIGURE 10 CAGR PROJECTIONS 58
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR 59
2.3 DATA TRIANGULATION APPROACH 61
FIGURE 12 DATA TRIANGULATION METHODOLOGY 61
 
2.4 MARKET SHARE ESTIMATION 62
2.5 ASSUMPTIONS FOR THE STUDY 62
2.6 LIMITATIONS 62
2.6.1 METHODOLOGY-RELATED LIMITATIONS 62
2.7 RISK ASSESSMENT 63
TABLE 2 RISK ASSESSMENT: PHARMACEUTICAL DRUG DELIVERY MARKET 63
3 EXECUTIVE SUMMARY 64
FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD BILLION) 64
FIGURE 14 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION) 65
FIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2021 VS. 2026 (USD BILLION) 66
FIGURE 16 GEOGRAPHIC ANALYSIS: PHARMACEUTICAL DRUG DELIVERY MARKET 67
4 PREMIUM INSIGHTS 69
4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW 69
FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH 69
4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY 70
FIGURE 18 THE HOSPITALS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET IN 2020 70
4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
FIGURE 19 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD 71
4.4 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION (2019-2026) 72
FIGURE 20 NORTH AMERICA TO DOMINATE THE PHARMACEUTICAL DRUG DELIVERY MARKET DURING FORECAST PERIOD 72
4.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS 73
FIGURE 21 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 73
5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
TABLE 3 PHARMACEUTICAL DRUG DELIVERY MARKET: IMPACT ANALYSIS 74
5.2.1 MARKET DRIVERS 75
5.2.1.1 Rising prevalence of chronic diseases 75
5.2.1.2 Growth in the biologics market 76
TABLE 4 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2020) 76
5.2.1.3 Technological advancements and new product launches 77
5.2.1.4 Increasing investments in pharmaceutical R&D 79
FIGURE 22 NUMBER OF PHARMACEUTICAL COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020) 79
FIGURE 23 GLOBAL PHARMA R&D SPENDING (2016–2020) 79
5.2.2 MARKET RESTRAINTS 80
5.2.2.1 Risk of needlestick injuries 80
5.2.3 MARKET OPPORTUNITIES 81
5.2.3.1 Self-administration and home care 81
5.2.3.2 Rising demand for biosimilars and biologics 81
5.2.4 MARKET CHALLENGES 82
5.2.4.1 Pricing pressure 82
5.3 COVID-19 IMPACT ON THE PHARMACEUTICAL DRUG DELIVERY MARKET 82
5.4 INDUSTRY TRENDS 84
5.4.1 INCREASING ADOPTION OF WEARABLE DRUG DELIVERY TECHNOLOGIES 84
5.4.2 ADVANCEMENTS IN TECHNOLOGIES AND DESIGNS 84
5.5 REGULATORY ANALYSIS 85
TABLE 5 REGULATORY SCENARIO BY COUNTRY 85
5.6 PORTER’S FIVE FORCES ANALYSIS 88
TABLE 6 PORTER’S FIVE FORCES ANALYSIS (2020): PHARMACEUTICAL DRUG DELIVERY MARKET 88
5.6.1 THREAT FROM NEW ENTRANTS 88
5.6.2 THREAT FROM SUBSTITUTES 88
5.6.3 BARGAINING POWER OF SUPPLIERS 89
5.6.4 BARGAINING POWER OF BUYERS 89
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 89
5.7 VALUE CHAIN ANALYSIS 90
FIGURE 24 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL DRUG DELIVERY MARKET 90
5.8 ECOSYSTEM MAPPING 91
FIGURE 25 ECOSYSTEM OF THE PHARMACEUTICAL DRUG DELIVERY MARKET 91
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 91
5.10 PATENT ANALYSIS 92
5.10.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 92
FIGURE 26 PATENT PUBLICATION, FILING, AND GRANT TRENDS (JANUARY 2011–OCTOBER 2021) 92
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 92
FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021) 93
FIGURE 28 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021) 94
TABLE 7 SOME PATENTS/ PATENT APPLICATIONS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET, 2020-2021 94
 
6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 96
6.1 INTRODUCTION 97
TABLE 8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 97
6.2 ORAL DRUG DELIVERY 98
TABLE 9 ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 98
TABLE 10 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 99
6.2.1 SOLID ORAL DRUGS 99
TABLE 11 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 100
TABLE 12 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION) 100
6.2.1.1 Tablets 101
6.2.1.1.1 The development of mini-tablets is a key trend in this market segment 101
TABLE 13 TABLETS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 102
6.2.1.2 Capsules 102
6.2.1.2.1 The easy absorption of drugs and decreased irritation in the GI tract drive the use of capsules 102
TABLE 14 CAPSULES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 103
6.2.1.3 Powders 103
6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms 103
TABLE 15 POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 104
6.2.1.4 Pills 105
6.2.1.4.1 The rising incidence of target ailments to propel the growth of the pills market 105
TABLE 16 PILLS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 105
6.2.2 LIQUID ORAL DRUGS 106
TABLE 17 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 106
TABLE 18 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 107
6.2.2.1 Syrups 107
6.2.2.1.1 Syrups can be easily administered to patients with swallowing difficulties 107
TABLE 19 ORAL SYRUPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 108
6.2.2.2 Solutions 108
6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients 108
TABLE 20 ORAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 109
6.2.3 SEMI SOLID ORAL DRUGS 109
TABLE 21 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 110
TABLE 22 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION) 110
6.2.3.1 Gels 111
6.2.3.1.1 Gels are used for controlled drug release 111
TABLE 23 ORAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 111
6.2.3.2 Emulsions 112
6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis 112
TABLE 24 ORAL EMULSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 112
6.2.3.3 Elixirs 113
6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances 113
TABLE 25 ORAL ELIXIRS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 113
6.3 INJECTABLE DRUG DELIVERY 114
TABLE 26 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 115
TABLE 27 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 115
6.3.1 CONVENTIONAL INJECTION DEVICES 116
TABLE 28 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 116
6.3.1.1 By material 117
TABLE 29 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 117
6.3.1.1.1 Glass Syringes 117
6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safest materials to store biological drugs 117
TABLE 30 GLASS SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118
6.3.1.1.2 Plastic Syringes 118
6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts 118
TABLE 31 PLASTIC SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 119
6.3.1.2 By product 119
TABLE 32 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 120
6.3.1.2.1 Fillable syringes 120
6.3.1.2.1.1 Ease of use and the variable dosing formulations of fillable syringes to drive the market growth 120
TABLE 33 FILLABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 121
6.3.1.2.2 Prefilled syringes 121
6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety 121
TABLE 34 PREFILLED SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
6.3.1.3 By usability 123
TABLE 35 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 123
6.3.1.3.1 Reusable syringes 123
6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean 123
TABLE 36 REUSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 124
6.3.1.3.2 Disposable syringes 124
6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience 124
TABLE 37 DISPOSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 125
6.3.2 SELF-INJECTION DEVICES 125
TABLE 38 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 126
TABLE 39 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 127
6.3.2.1 Needle-free injectors 127
6.3.2.1.1 Needle-free injectors enable faster drug delivery and show better reproducibility as compared to invasive drug delivery systems 127
TABLE 40 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 128
6.3.2.2 Autoinjectors 128
6.3.2.2.1 Autoinjectors to provide improved patient satisfaction as compared to manual injections 128
TABLE 41 AUTOINJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 129
6.3.2.3 Pen injectors 129
6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week 129
TABLE 42 COMMERCIALLY AVAILABLE KEY PEN INJECTORS 130
TABLE 43 PEN INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 130
6.3.2.4 Wearable injectors 131
6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth 131
TABLE 44 WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 131
6.3.3 OTHER INJECTOR DEVICES 132
TABLE 45 OTHER INJECTORS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 132
6.4 TOPICAL DRUG DELIVERY 133
TABLE 46 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 133
TABLE 47 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 134
6.4.1 LIQUID FORMULATIONS 134
TABLE 48 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 134
TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 135
6.4.1.1 Solutions 135
6.4.1.1.1 Ease of use and ready availability of the dosage form to support market growth 135
TABLE 50 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 136
 
6.4.1.2 Suspensions 136
6.4.1.2.1 Factors such as the high rate of bioavailability and the controlled onset of action to support the growth of the topical suspensions market 136
TABLE 51 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 137
6.4.2 SEMI SOLID FORMULATIONS 137
TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 138
TABLE 53 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 138
6.4.2.1 Creams 139
6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions 139
TABLE 54 TOPICAL CREAMS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 139
6.4.2.2 Gels 140
6.4.2.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels 140
TABLE 55 TOPICAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 140
6.4.2.3 Ointments 141
6.4.2.3.1 Ointments are widely used in analgesic indications 141
TABLE 56 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 141
6.4.2.4 Pastes 142
6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation 142
TABLE 57 TOPICAL PASTES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 142
6.4.2.5 Lotions 143
6.4.2.5.1 Easy administration of lotions to drive the demand among end users 143
TABLE 58 TOPICAL LOTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 143
6.4.3 SOLID FORMULATIONS 144
TABLE 59 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 144
TABLE 60 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 144
6.4.3.1 Suppositories 145
6.4.3.1.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug 145
TABLE 61 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 145
6.4.3.2 Powders 146
6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight 146
TABLE 62 TOPICAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 146
6.4.4 TRANSDERMAL PRODUCTS 147
TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 147
TABLE 64 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2019–2026 (USD BILLION) 148
6.4.4.1 Transdermal patches 148
6.4.4.1.1 Transdermal patches to prevent the premature metabolization of the drug through the liver 148
TABLE 65 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 149
6.4.4.2 Transdermal gels 150
6.4.4.2.1 Transdermal gels to help in a faster release of drugs on the target site 150
TABLE 66 TRANSDERMAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 150
6.5 OCULAR DRUG DELIVERY 151
TABLE 67 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 151
TABLE 68 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 152
6.5.1 LIQUID FORMULATIONS 152
TABLE 69 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 153
TABLE 70 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 153
6.5.1.1 Eye drops 154
6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth 154
TABLE 71 COMMERCIALLY AVAILABLE EYE DROPS 154
TABLE 72 EYE DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 155
6.5.1.2 Liquid sprays 155
6.5.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops 155
TABLE 73 LIQUID SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 156
6.5.2 SEMI SOLID FORMULATIONS 156
TABLE 74 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 157
TABLE 75 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 157
6.5.2.1 Gels 158
6.5.2.1.1 The high viscosity of drugs, prolonged drug release, and the ease of drug administration are factors contributing to market growth 158
TABLE 76 OCULAR GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 158
6.5.2.2 Eye ointments 159
6.5.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug 159
TABLE 77 EYE OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 160
6.5.3 OCULAR DEVICES 160
TABLE 78 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 161
TABLE 79 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 161
6.5.3.1 Drug-coated contact lenses 162
6.5.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses 162
TABLE 80 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 162
6.5.3.2 Ocular inserts 163
6.5.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye 163
TABLE 81 OCULAR INSERTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 163
6.6 PULMONARY DRUG DELIVERY 164
TABLE 82 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 164
TABLE 83 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 165
6.6.1 METERED-DOSE INHALERS 165
6.6.1.1 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath 165
TABLE 84 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2019–2026 (USD BILLION) 166
6.6.2 DRY POWDER INHALERS 166
6.6.2.1 Dry powder inhaler formulations are chemically more stable than their counterparts 166
TABLE 85 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2019–2026 (USD BILLION) 167
6.6.3 NEBULIZERS 167
TABLE 86 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 168
TABLE 87 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2019–2026 (USD BILLION) 168
6.6.3.1 Jet nebulizers 169
6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market 169
TABLE 88 JET NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 169
6.6.3.2 Ultrasonic nebulizers 170
6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle 170
TABLE 89 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 170
6.6.3.3 Soft mist nebulizers 171
6.6.3.3.1 Soft mist nebulizers are preferred for the treatment of severe COPD 171
TABLE 90 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 171
6.7 NASAL DRUG DELIVERY 172
TABLE 91 NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 172
TABLE 92 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 173
 
6.7.1 NASAL DROPS 173
6.7.1.1 Nasal drops are considered more efficient than nasal sprays 173
TABLE 93 NASAL DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 174
6.7.2 NASAL SPRAYS 174
6.7.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing 174
TABLE 94 NASAL SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 175
6.7.3 NASAL POWDERS 175
6.7.3.1 The absence of preservatives and superior stability of formulations are some of the advantages associated with nasal powders 175
TABLE 95 NASAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 176
6.7.4 NASAL GELS 176
6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients 176
TABLE 96 NASAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 177
6.8 TRANSMUCOSAL DRUG DELIVERY 177
TABLE 97 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 178
TABLE 98 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 179
6.8.1 ORAL FORMULATIONS 179
TABLE 99 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 180
TABLE 100 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 180
6.8.1.1 Buccal drug delivery 181
6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies 181
TABLE 101 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 181
6.8.1.2 Sublingual drug delivery 182
6.8.1.2.1 The rate of drug absorption through the sublingual route is 3–10 times higher than the oral route 182
TABLE 102 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 183
6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES 183
TABLE 103 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 184
TABLE 104 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 184
6.8.2.1 Rectal transmucosal drug delivery 185
6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature 185
TABLE 105 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 185
6.8.2.2 Vaginal transmucosal drug delivery 186
6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration 186
TABLE 106 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 186
6.9 IMPLANTABLE DRUG DELIVERY 187
TABLE 107 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 187
TABLE 108 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 188
6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY 188
6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionizing radiation 188
TABLE 109 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 189
6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY 189
6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants 189
TABLE 110 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 190
7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION 191
7.1 INTRODUCTION 192
7.2 COVID-19 IMPACT, BY APPLICATION 192
TABLE 111 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 193
7.3 INFECTIOUS DISEASES 193
7.3.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH 193
TABLE 112 PHARMACEUTICAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 195
7.4 CANCER 195
7.4.1 CANCER TO FORM A KEY THERAPEUTIC APPLICATION SEGMENT FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 195
FIGURE 29 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020) 196
FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS) 196
TABLE 113 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) 197
TABLE 114 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD BILLION) 198
7.5 CARDIOVASCULAR DISEASES 198
7.5.1 INCREASING PREVALENCE OF CVDS AND INCREASING INNOVATION IN THE PHARMACEUTICAL DRUG DELIVERY SEGMENT TO PROPEL MARKET GROWTH 198
TABLE 115 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 199
TABLE 116 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 200
 
7.6 DIABETES 200
7.6.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 200
FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS) 201
TABLE 117 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD BILLION) 202
7.7 RESPIRATORY DISEASES 202
7.7.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE THE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY 202
TABLE 118 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020) 203
TABLE 119 PHARMACEUTICAL DRUG DELIVERY MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 204
7.8 CENTRAL NERVOUS SYSTEM DISORDERS 204
7.8.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS 204
TABLE 120 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION) 206
7.9 AUTOIMMUNE DISEASES 206
7.9.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD 206
TABLE 121 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 207
7.10 OTHER APPLICATIONS 208
7.10.1 OPHTHALMIC DISORDERS 208
7.10.2 ENDOCRINE DISORDERS 208
TABLE 122 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 209
8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 210
8.1 INTRODUCTION 211
TABLE 123 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 211
8.2 HOSPITALS 212
8.2.1 HOSPITALS DOMINATE THE GLOBAL MARKET WITH THE HIGH VOLUME OF PRESCRIPTIONS FOR INPATIENT AND OUTPATIENT VISITS 212
TABLE 124 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD BILLION) 213
8.3 AMBULATORY SURGERY CENTERS/CLINICS 214
8.3.1 INCREASING PREFERENCE FOR AMBULATORY SURGERY CENTERS TO RESULT IN A SIGNIFICANT RISE IN DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 214
TABLE 125 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD BILLION) 215
 
8.4 HOME CARE SETTINGS 215
8.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 215
TABLE 126 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026 (USD BILLION) 216
8.5 DIAGNOSTIC CENTERS 216
8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH 216
TABLE 127 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2019–2026 (USD BILLION) 217
8.6 OTHER FACILITIES OF USE 217
TABLE 128 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2019–2026 (USD BILLION) 218
9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION 219
9.1 INTRODUCTION 220
FIGURE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2020) 220
TABLE 129 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2019–2026 (USD BILLION) 221
9.2 NORTH AMERICA 221
FIGURE 33 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 223
TABLE 130 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 224
TABLE 131 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 224
TABLE 132 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 225
TABLE 133 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 225
TABLE 134 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 225
TABLE 135 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 226
TABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 226
TABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 226
TABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 227
TABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 227
TABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 227
TABLE 141 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 228
TABLE 142 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 228
TABLE 143 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 228
TABLE 144 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 229
TABLE 145 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 229
TABLE 146 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 229
TABLE 147 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 148 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 149 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 150 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 151 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 152 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 153 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 232
TABLE 154 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 232
TABLE 155 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 232
TABLE 156 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 233
TABLE 157 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 233
TABLE 158 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 234
9.2.1 US 234
9.2.1.1 The US to dominate the North American pharmaceutical drug delivery market 234
TABLE 159 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 235
TABLE 160 US: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 235
TABLE 161 US: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 236
TABLE 162 US: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 236
TABLE 163 US: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 236
TABLE 165 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 237
TABLE 166 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES,
BY MATERIAL, 2019–2026 (USD BILLION) 237
TABLE 167 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 237
TABLE 168 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 238
TABLE 169 US: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 238
TABLE 170 US: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 238
TABLE 171 US: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 239
TABLE 172 US: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 239
TABLE 173 US: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 239
TABLE 174 US: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 240
TABLE 175 US: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 240
TABLE 176 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 240
TABLE 177 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 241
TABLE 178 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 241
TABLE 179 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 241
TABLE 180 US: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 242
TABLE 181 US: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 242
TABLE 182 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 242
TABLE 183 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 184 US: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 185 US: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 186 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 244
TABLE 187 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 244

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（中枢神経系作用薬）の最新刊レポート

MarketsandMarkets社の中枢神経系作用薬分野での最新刊レポート

本レポートと同じKEY WORD（pharmaceutical drug）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20　10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.